160 related articles for article (PubMed ID: 34836971)
1. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma.
Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J
Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971
[TBL] [Abstract][Full Text] [Related]
2. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
[TBL] [Abstract][Full Text] [Related]
3. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
[TBL] [Abstract][Full Text] [Related]
4. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.
Hsu JY; Danis EP; Nance S; O'Brien JH; Gustafson AL; Wessells VM; Goodspeed AE; Talbot JC; Amacher SL; Jedlicka P; Black JC; Costello JC; Durbin AD; Artinger KB; Ford HL
Cell Rep; 2022 Feb; 38(5):110323. PubMed ID: 35108532
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9-Mediated Bioluminescent Tagging of Endogenous Proteins by Fluorescent Protein-Assisted Cell Sorting.
Hawley RG; Hawley TS
Methods Mol Biol; 2024; 2779():273-286. PubMed ID: 38526790
[TBL] [Abstract][Full Text] [Related]
6. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R
Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL.
Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302
[TBL] [Abstract][Full Text] [Related]
8. Transforming Growth Factor Beta and Alveolar Rhabdomyosarcoma: A Challenge of Tumor Differentiation and Chemotherapy Response.
Bhushan B; Iranpour R; Eshtiaghi A; da Silva Rosa SC; Lindsey BW; Gordon JW; Ghavami S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474036
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract][Full Text] [Related]
10. Rhabdomyosarcoma: current challenges and their implications for developing therapies.
Hettmer S; Li Z; Billin AN; Barr FG; Cornelison DD; Ehrlich AR; Guttridge DC; Hayes-Jordan A; Helman LJ; Houghton PJ; Khan J; Langenau DM; Linardic CM; Pal R; Partridge TA; Pavlath GK; Rota R; Schäfer BW; Shipley J; Stillman B; Wexler LH; Wagers AJ; Keller C
Cold Spring Harb Perspect Med; 2014 Nov; 4(11):a025650. PubMed ID: 25368019
[TBL] [Abstract][Full Text] [Related]
11. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.
Panditharatna E; Marques JG; Wang T; Trissal MC; Liu I; Jiang L; Beck A; Groves A; Dharia NV; Li D; Hoffman SE; Kugener G; Shaw ML; Mire HM; Hack OA; Dempster JM; Lareau C; Dai L; Sigua LH; Quezada MA; Stanton AJ; Wyatt M; Kalani Z; Goodale A; Vazquez F; Piccioni F; Doench JG; Root DE; Anastas JN; Jones KL; Conway AS; Stopka S; Regan MS; Liang Y; Seo HS; Song K; Bashyal P; Jerome WP; Mathewson ND; Dhe-Paganon S; Suvà ML; Carcaboso AM; Lavarino C; Mora J; Nguyen QD; Ligon KL; Shi Y; Agnihotri S; Agar NYR; Stegmaier K; Stiles CD; Monje M; Golub TR; Qi J; Filbin MG
Cancer Discov; 2022 Dec; 12(12):2880-2905. PubMed ID: 36305736
[TBL] [Abstract][Full Text] [Related]
12. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
[TBL] [Abstract][Full Text] [Related]
13. Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma.
Wei Y; Qin Q; Yan C; Hayes MN; Garcia SP; Xi H; Do D; Jin AH; Eng TC; McCarthy KM; Adhikari A; Onozato ML; Spentzos D; Neilsen GP; Iafrate AJ; Wexler LH; Pyle AD; Suvà ML; Dela Cruz F; Pinello L; Langenau DM
Nat Cancer; 2022 Aug; 3(8):961-975. PubMed ID: 35982179
[TBL] [Abstract][Full Text] [Related]
14. Smyd1: Implications for novel approaches in rhabdomyosarcoma therapy.
Berkholz J; Schmitt A; Fragasso A; Schmid AC; Munz B
Exp Cell Res; 2024 Jan; 434(2):113863. PubMed ID: 38097153
[TBL] [Abstract][Full Text] [Related]
15. TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma.
Gallo-Oller G; Pons G; Sansa-Girona J; Navarro N; Zarzosa P; García-Gilabert L; Cabré-Fernandez P; Guillén Burrieza G; Valero-Arrese L; Segura MF; Lizcano JM; Sánchez de Toledo J; Moreno L; Gallego S; Roma J
Exp Hematol Oncol; 2024 Apr; 13(1):38. PubMed ID: 38581035
[TBL] [Abstract][Full Text] [Related]
16. The 3D chromatin landscape of rhabdomyosarcoma.
Wang M; Sreenivas P; Sunkel BD; Wang L; Ignatius M; Stanton BZ
NAR Cancer; 2023 Sep; 5(3):zcad028. PubMed ID: 37325549
[TBL] [Abstract][Full Text] [Related]
17. PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets.
Zhang S; Wang J; Liu Q; McDonald WH; Bomber ML; Layden HM; Ellis J; Borinstein SC; Hiebert SW; Stengel KR
Mol Cell; 2022 Dec; 82(23):4428-4442.e7. PubMed ID: 36395771
[TBL] [Abstract][Full Text] [Related]
18. BET Bromodomain Degradation Disrupts Function but Not 3D Formation of RNA Pol2 Clusters.
Chin DH; Osman I; Porch J; Kim H; Buck KK; Rodriguez J; Carapia B; Yan D; Moura SB; Sperry J; Nakashima J; Altman K; Altman D; Gryder BE
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259348
[TBL] [Abstract][Full Text] [Related]
19. The Wnt-pathway corepressor TLE3 interacts with the histone methyltransferase KMT1A to inhibit differentiation in Rhabdomyosarcoma.
Kalita B; Sahu S; Bharadwaj A; Panneerselvam L; Martinez-Cebrian G; Agarwal M; Mathew SJ
Oncogene; 2024 Feb; 43(7):524-538. PubMed ID: 38177411
[TBL] [Abstract][Full Text] [Related]
20. Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse.
de Traux de Wardin H; Dermawan JK; Merlin MS; Wexler LH; Orbach D; Vanoli F; Schleiermacher G; Geoerger B; Ballet S; Guillemot D; Frouin E; Cyrille S; Delattre O; Pierron G; Antonescu CR
NPJ Precis Oncol; 2023 Sep; 7(1):96. PubMed ID: 37730754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
